2024 NCODA Spring Forum
CE Registration & Claiming Credit

Register for CE by clicking on this link:
https://www.lecturepanda.com/r/2024NCODASpringForum

Important Notes:

• Please take the pre-assessment for each CE session you plan on attending **BEFORE** the session begins or within the first 15 minutes of each CE session.
  - For Live CE events, the pre-tests will be unavailable 15 minutes after it begins. This is to prevent obtaining invalid data from participants completing the pre-test after the session has ended.

• You may also register for all CEs by scanning the QR code on the sign(s) near the entrance of where the CE sessions will be held.

• Credit requirements must be completed within 60 days of the program activity date (June 4, 2024).

• Upon completion, credit will be transmitted electronically to ACPE (for pharmacists and pharmacy technicians) and other accrediting bodies if you are a nurse or physician.
  - All transmitted credit should be viewable in your CPE monitor profile within 24 hours for pharmacists and pharmacy technicians.
NCODA 2024 Spring Forum
Physician and Registered Nurse Sessions CE Information
April 3-5, 2024 | Dallas, TX
Jointly provided by Partners for Advancing Clinical Education (PACE) and NCODA

**Target Audience**
This conference is intended for oncology healthcare providers that include; pharmacists, pharmacy technicians, physicians and nurses who care for patients within oncology.

**Individual CME/CNE Session Educational Objectives**
Upon completion of each session, participants should be able to:

**Precision Oncology – Unlocking Therapeutic Opportunities Through Genomics**
1.0 CME credit/CNE contact hour
- Explain the basics of precision oncology.
- Discuss how to interpret a genomic test report for patients with cancer.
- Identify how tumor genomic sequencing results guide cancer treatment decisions in real-world patient cases.
- Describe the role of the pharmacist as molecular oncology subspecialists.

**Managing Oncologic Toxicities: Assessment, Diagnosis, & Treatment**
1.0 CME credit/CNE contact hour
- Articulate appropriate adverse events grading through utilization of Common Terminology Criteria for Adverse Events (CTCAE).
- Describe surveillance strategies to assess patients for symptoms of cancer and cancer treatment related toxicities.
- Identify interventions to treat toxicities resulting from cancer and/or cancer treatments.

**Updates in Chronic Lymphocytic Leukemia**
1.0 CME credit/CNE contact hour
- Distinguish front line and relapsed/refractory treatment of CLL/SLL.
- Apply recent literature and updates to guidelines to distinguish between new agents and therapy options for frontline and relapsed/refractory treatment of CLL/SLL.
- Differentiate treatment options based on patient specific considerations.
- Compare and contrast bruton tyrosine kinase (BTK) inhibitor dosing schedules and toxicity profiles.

**Navigating Opportunities & Vulnerabilities in Cancer Care**
1.0 CME credit/CNE contact hour
- Identify key areas of patient assessment, based on social determinants of health (SDOH), for individuals receiving care for cancer. PTN
- Discuss care interventions for patients, within each domain of SDOH, when an opportunity or vulnerability is identified. PTN
- Discuss the importance of collaboration and communication within the medically integrated team. PTN
- Recognize the impact of early intervention once an opportunity or vulnerability is identified.
Fertility Preservation & Sexual Side Effects

1.0 CME credit/CNE contact hour

- Describe short- and long-term fertility consequences patients receiving treatment for breast cancer may experience.
- Apply evidence-based strategies to support fertility preservation in diverse breast cancer patient populations receiving systemic therapies.
- Identify potential sexual health implications systemic treatment can have on patients with breast cancer.
- Explore evidence-based approaches to preventing and addressing sexual health challenges in diverse patient populations with breast cancer.

The Power of Metrics: Harnessing Data to Advance & Support the Success of an Oral Anticancer Medication Program

1.0 CME credit/CNE contact hour

- State advantages of tracking metrics in the oral anticancer medication (OAM) setting.
- Identify metrics that can be used in different OAM settings to benefit patients or the facility.
- Demonstrate how to apply three metrics for use in one’s own OAM practice setting.

Advancements in Pharmacy Safety: Navigating USP 797 & 800 Updates & Mastering Aseptic Techniques

1.0 CME credit/CNE contact hour

- Discuss the importance of United States Pharmacopeia (USP), including UPS chapters <797> and <800> as they relate to patient safety.
- Summarize the standard revisions for USP General Chapters <797> and <800>.
- Describe the practice settings that are affected by USP General Chapters <797> and <800> now that they are enforceable.
- Outline best practices for aseptic technique to minimize contamination.

To Infinity and Beyond 5FU: Updates in the Treatment of Metastatic Colorectal Cancer

0.75 CME credit/CNE contact hour

- Identify treatment options for patients with refractory metastatic colorectal cancer.
- Recognize appropriate treatment regimens for patients with refractory metastatic colorectal cancer based on cancer biomarkers and side effect profiles.
- List pertinent counseling points for medications used in refractory metastatic colorectal cancer.

New Kids On The Block: Who Are They And How Did They Get Here? Clinical Trial Overview

1.0 CME credit/CNE contact hour

- Describe the types of trials utilized when evaluating new pharmaceutical agents.
- Explain the barriers to clinical trial participation including access to trials and out-of-pocket costs.
- Discuss the use of recently approved oral oncolytic agents.
- Identify potential side effects, supportive care measures, and tolerability concerns for recently approved pediatric oral oncolytic agents.
Breast Cancer Treatment Updates: Strategies for Best Patient Care

1.0 CME credit/CNE contact hour

- Describe HER2-positive breast cancer disease biology, diagnosis, and therapies.
- Review the clinical management of early-stage HER2+ breast cancer.
- Summarize the clinical management of metastatic HER2+ breast cancer.
- Discuss the clinical management of CNS metastasis from HER2+ breast cancer.

Faculty and Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

<table>
<thead>
<tr>
<th>Faculty</th>
<th>Relevant Financial Relationships</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Freydman, PharmD, BCOP</td>
<td>Has no relevant financial relationships.</td>
</tr>
<tr>
<td>April Hallatt, BSN, RN, OCN</td>
<td>Speaker: Merck</td>
</tr>
<tr>
<td>Todd. C Knepper, PharmD</td>
<td>Advisory Board Member: AstraZeneca</td>
</tr>
<tr>
<td>Dawn Landolph, BSN, MPA, RN, OCN</td>
<td>Has no relevant financial relationships.</td>
</tr>
<tr>
<td>Dallas Lawry, DNP, FNP-C, AOCNP</td>
<td>Advisory Board Member: BMS, Takeda, G1 Therapeutics</td>
</tr>
<tr>
<td>Debra Lawry, RN, OCN</td>
<td>Has no relevant financial relationships.</td>
</tr>
<tr>
<td>Dat Le, PharmD, BCOP</td>
<td>Has no relevant financial relationships.</td>
</tr>
<tr>
<td>Kristine B. LeFebvre, DNP, RN, NPD-BC, AOCNP</td>
<td>Has no relevant financial relationships.</td>
</tr>
<tr>
<td>Maya Leiva, PharmD, BCOP, APP, APh</td>
<td>Speaker: BMS, Ipsen, Gilead, DSI</td>
</tr>
<tr>
<td>Jack Malespini, PharmD, BCOP</td>
<td>Has no relevant financial relationships.</td>
</tr>
<tr>
<td>Jean Meyer, CPhT</td>
<td>Has no relevant financial relationships.</td>
</tr>
<tr>
<td>Cesar Santa-Maria, MD, MSCI</td>
<td>Principal Investigator: Pfizer, Novarts, AstraZeneca, GSK, BMS, Genentech, Merck, Celldex; Advisory Board Member: Seattle Genetics, BMS, Pfizer, Merck</td>
</tr>
<tr>
<td>Dana Slusher, BSN, RN, OCN</td>
<td>Has no relevant financial relationships.</td>
</tr>
<tr>
<td>Andrea Skafel MSc, CCRP</td>
<td>Has no relevant financial relationships.</td>
</tr>
<tr>
<td>Ally Thrall, PharmD, BCPPS</td>
<td>Speaker: BTG International</td>
</tr>
<tr>
<td>Emily Zimdars, BA, CPhT</td>
<td>Has no relevant financial relationships.</td>
</tr>
</tbody>
</table>

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and NCODA. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education*
PACE designates this live activity for a maximum of 5.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education*
The maximum number of hours awarded for this Continuing Nursing Education activity is 5.75 contact hours.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions for Credit
CE Credit for the NCODA 2024 Spring Forum can be claimed through the LecturePanda platform. To register, please visit: https://www.lecturepanda.com/r/2024NCODASpringForum